Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.76 |
| ▸ | DPP4 | P27487 | 1/20 | 0.76 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 9/20 | 0.59 |
| ▸ | FDPS | P14324 | 1/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886157 | 1.00 | TTR (0.76) | TTRDPP4MAOBCYP3A4CA12 | |
| SCHEMBL16794973 | 0.88 | TTR (0.66) | TTRDPP4MAOBCYP3A4CA12 | |
| SCHEMBL30807058 | 0.88 | TTR (0.66) | TTRDPP4MAOBCYP3A4CA12 | |
| SCHEMBL16794971 | 0.88 | TTR (0.66) | TTRDPP4MAOBCYP3A4CA12 | |
| Ethyl Caffeate SCHEMBL31059266 | 0.86 | TTR (1.00) | TTRDPP4MAOBCYP3A4CA12 | |
| Ethyl Caffeate SCHEMBL22196845 | 0.86 | TTR (1.00) | TTRDPP4MAOBCYP3A4CA12 | |
| Ethyl Caffeate SCHEMBL782032 | 0.86 | TTR (1.00) | TTRDPP4MAOBCYP3A4CA12 | |
| Ethyl Caffeate SCHEMBL782033 | 0.86 | TTR (1.00) | TTRDPP4MAOBCYP3A4CA12 | |
| Ethyl Caffeate SCHEMBL30286241 | 0.86 | TTR (1.00) | TTRDPP4MAOBCYP3A4CA12 | |
| Ethyl Caffeate SCHEMBL30602576 | 0.86 | TTR (1.00) | TTRDPP4MAOBCYP3A4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1047425-A4 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7339065-B2 | Design and synthesis of optimized ligands for PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | THE UNIVERSITY OF MISSISSIPPI | 2007-05-03 | — | — | US | disclosed |
| EP-1040111-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6268378-B1 | TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH. | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| EP-1047425-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-1040111-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6066648-A | USEFUL IN INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH | MERCK & CO., INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-6017926-A | Integrin receptor antagonists | MERCK & CO., INC. (US) | 2000-01-25 | — | — | US | disclosed |
| WO-1999031099-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999030709-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | PPARD, PPARA, PPARG | TTR 2521/4885DPP4 579/4885MAOB 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.